Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down prior to trading on Friday . The stock had previously closed at $19.33, but opened at $18.52. Ascentage Pharma Group International shares last traded at $18.0660, with a volume of 165 shares traded.

Wall Street Analyst Weigh In

Several analysts recently issued reports on AAPG shares. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective for the company. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, BTIG Research reissued a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to MarketBeat.com, Ascentage Pharma Group International currently has an average rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Trading Down 5.4%

The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. The company has a fifty day moving average price of $18.56 and a 200-day moving average price of $22.42.

Institutional Trading of Ascentage Pharma Group International

A number of large investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the 2nd quarter worth approximately $391,000. UBS Group AG boosted its position in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the third quarter valued at $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.